Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Non-Current Deffered Revenue (2023 - 2024)

Telix Pharmaceuticals has reported Non-Current Deffered Revenue over the past 2 years, most recently at $2.2 million for Q4 2024.

  • Quarterly Non-Current Deffered Revenue fell 72.84% to $2.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2024, down 72.84% year-over-year, with the annual reading at $2.0 million for FY2024, 75.53% down from the prior year.
  • Non-Current Deffered Revenue was $2.2 million for Q4 2024 at Telix Pharmaceuticals, down from $7.9 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $7.9 million in Q4 2023 and troughed at $2.2 million in Q4 2024.